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Increased platelet-derived growth factor in the kidneys of cyclosporin-
treated rats. We have examined the histological changes and the distri-
bution of immunoreactive platelet-derived growth factor (PDGF) in the
kidneys of Sprague-Dawley rats injected with cyclosporin A (C5A, 25
mg/kg/day), Control rats were injected with the olive oil vehicle alone.
Groups of rats were killed after 1, 2, 3, 4 weeks of injection and 8 weeks
after a 4 week period of injection. Additional controls included groups of
rats injected with different doses of CsA and a group of rats subjected to
chronic renal ischemia by partial ligation of the aorta. CsA-treated rats
gained weight more slowly than olive oil-treated controls (45%, P < 0.05).
In rats injected with CsA, a significant increase in serum creatinine
concentration (64 2 .tmolIliter vs. 39 1 molIliter, P < 0.01) and a
reduction in creatinine clearance rates (0.23 0.07 ml/min/100 g body wt
vs. 0.43 0.07 mI/min/IQO g body wt, P < 0.01) occurred after 3 weeks.
After 1 week of CsA treatment, segments of the walls of some afferent and
intralobular arterioles were thickened and stained strongly by the periodic
acid Schiff (PAS) procedure. Immunostainable PDGF-BB and PDGF-AB
were detected within short segments of the afferent and intralobular
arterioles of the kidneys of CsA-treated rats and in the kidneys subjected
to renal isehemia but not in tissue from other control animals. No PAS
staining or immunostaining was evident in CsA treated kidneys eight
weeks after the discontinuation of treatment. We conclude that CsA-
induced ischemia results in increased accumulation of PDGF in the walls
of renal arterioles.
The introduction of cyclosporin (CsA) had a considerable
impact on allograft survival [1, 2]. Unfortunately, CsA has proven
to be nephrotoxic [3—5]. This nephrotoxicity is characterized
functionally by increased renal vascular resistance, decreased
renal blood flow and reduced glomerular filtration rate [6—8], and
morphologically by tubular atrophy, arteriolar changes and inter-
stitial fibrosis [9, 10].
The CsA-induced alteration of renal hemodynamics has been
attributed to increased renal vascular tone, predominantly in the
afferent arterioles [11]. A wide range of systemic hormones and
renal autacoids has been implicated including catecholamines [6,
12, 13], the renin-angiotensin-aldosterone system [6, 12, 14, 15]
and prostaglandins, in particular thromboxane A2 [16—19].
Vasoconstricting growth factors may also play a role in CsA-
induced renal ischemia. Renal endothelin is increased in experi-
mental models of CsA-induced renal dysfunction [20, 21] and in a
recent study, the administration of an endothelin receptor antag-
onist reduced CsA renal vasoconstriction in rats [22]. Platelet-
derived growth factor (PDGF) is another growth promoting
peptide which has been shown to have a vasoconstrictive effect on
vascular smooth muscle cells [23]. It has also been shown to be a
mediator of fibrosis [24, 25], and increased expression of PDGF
has been demonstrated in atherosclerotic plaques and other
vascular proliferative lesions [26, 271. The possibility exists there-
fore that PDGF is involved in CsA-induced vasoconstriction and
fibrosis.
In this study, we have examined the morphological changes and
the localization of immunoreactive PDGF in the kidneys of
CsA-injected rats. As renal ischemia is implicated in CsA neph-
rotoxicity, we have also analyzed the distribution of PDGF in rat
kidneys subjected to chronic ischemia.
Methods
Animals
Adult male Sprague-Dawley rats (Sheffield University strain)
weighing 250 to 300 g were used. They were housed two to three
to a cage at a constant temperature of 20°C and 45% humidity on
12:12 hours light/dark cycle. The rats were normally allowed free
access to food and tap water, with the exception of one group of
control rats whose food and water intake was restricted to
amounts similar to those consumed by paired CsA-treated rats
(see below). All procedures were undertaken under license and
according to regulations laid down by H. M. Government, U.K.
(Animals Scientific Procedures Act, 1986).
Drug preparation
Cyclosporin was a gift of Sandoz UK Ltd. (Cambridge, UK).
The drug was dissolved first in ethanol (1 g/ml) and subsequently
diluted (1:10, vol:vol) with olive oil (low acidity, Sigma, Poole,
UK).
Experimental protocols
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Experimental rats received daily intraperitoneal injections of
CsA (25 mg/kg body wt) for up to 4 weeks. They were sacrificed
in groups (N = 3) at 1, 2, 3 and 4 weeks (N = 6). A further group
(N — 6) was injected for 4 weeks but killed 8 weeks after the last
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injection. Control animals were injected with an equivalent vol-
ume of the olive oil vehicle and were killed in groups (N =
equivalent number) at the same times. An additional group (N =
6) was placed in metabolic cages and injected daily with CsA for
3 weeks. Their daily food and water consumption was measured
and similar amounts were given to the paired control rats which
were injected with olive oil alone. This pair feeding was carried
out in order to identify the effects of food and water intake on
morphological and immunohistochemical changes within the kid-
neys.
All morphological and morphometric data reported in this
study were performed on kidneys from animals injected with 25
mg/kg/day. However, two further control groups were analyzed to
study the immunohistochemical localization of PDGF in response
to: (1) different doses of CsA (5, 7.5, 12.5 and 20 mg/kg/day, N =
3); (2) renal ischemia, as it is the likely mechanism of CsA-
induced nephrotoxicity.
Renal ischemia was induced in a group of rats (N = 6) by partial
ligation of the aorta between the origins of the right and left renal
arteries. Standardized constriction was produced by tying a silk
ligature tightly around the aorta and a needle stylet (outside
diameter 0.5 mm) placed alongside it. The needle was then
withdrawn [28]. This procedure resulted in obvious ischemia in
the left kidney manifested by immediate decrease in kidney
perfusion. These rats were killed after 2 weeks. During all of the
above experiments the rats were weighed weekly. Blood samples
were taken from tail vein at weekly intervals for the determination
of serum creatinine and CsA whole blood levels (by radioimmu-
noassay) [29]. Rats were placed in individual metabolic cages in
order to collect 24 hour urine for the estimation of creatinine
clearance rates. Systolic blood pressure was measured in non-
anesthetized but restrained animals by the tail cuff method prior
to sacrifice.
Tissue preparation
At the end of each experiment the rats were deeply anesthe-
tized with Sagatal (Pentobarbitone sodium, RMB Animal Health,
Dagenham, UK), weighed and samples of blood were withdrawn
for analysis. The kidneys were then perfused with phosphate
buffered saline (PBS) pH 7.2. When perfused, the kidneys were
removed and processed for light microscopy. Tissue was fixed
overnight in 4% formol calcium and embedded in low melting
point paraffin wax (56°C). Sections 4 jtm thick were stained
routinely with hematoxylin and eosin, by the periodic acid Schiff
(PAS) procedure and with Masson's trichrome stain.
Immunohistochemistiy
Sections 4 im thick were mounted on gelatinized glass slides,
dewaxed with xylene and hydrated with graded ethanol solutions
and water. They were then immersed in 0.6% H202 in methanol
for 20 minutes to quench endogenous peroxidase activity and then
stained immunohistochemically by an avidin-biotinylated horse-
radish peroxidase procedure using a commercially available kit
(ABC Elite Kit, Vector Laboratories, Peterborough, UK). Sec-
tions were first treated with dilute (1.5%) goat or horse serum
according to the species in which the secondary antibody was
raised. Then, sections were incubated overnight at 4°C in a humid
atmosphere with one of several antibodies (see below). Sections
were then incubated with the relevant secondary antibodies for 30
minutes, rinsed in PBS and incubated for 30 minutes with ABC
reagent (ABC Kit, Vector). 3-amino 9-ethyl carbazole was used as
the peroxidase substrate (AEC Kit, Vector) and sections were
counterstained with dilute aqueous hematoxylin (1:10, Shandon
Southern, Runcorn, UK) before being mounted in Glycergel
(DakoPatts, High Wycombe, UK).
Control incubations involved the substitution of the primary
antibody with an equivalent concentration of normal rabbit IgG or
the omission of the primary antibody. Also, the primary antibod-
ies were preabsorbed with the immunising antigens (PDGF-BB
and -AB, Genzyme Diagnostics, West Mailing, UK) and with
inappropriate antigens including renin (Sigma). For this, the
antigens were either adsorbed onto the wells of polylysine coated
or uncoated microtiter plates and preabsorption was carried out
overnight at 4°C at a molar ratio of 10:1 (antigen: antibody).
Primary antibodies
Primary antibodies were diluted with PBS containing 0.01%
crystalline grade bovine serum albumin (BSA, biotin free, Sigma)
and optimal working concentrations determined by titration.
Rabbit polyclonal anti-human PDGF-BB and mouse monoclonal
anti-human PDGF-AA were obtained from Genzyme Diagnos-
tics; goat polyclonal anti-human PDGF-AB was obtained from
Upstate Biotechnology, Lake Placid, New York USA. The mouse
monoclonal anti-alpha-smooth muscle actin1 (a-SMA1) was a gift
from Prof. G. Gabbiani, Geneva [30].
Light microscope morphometry
To establish the proportion of arteriole profiles which stained
for PDGF-BB, the frequency of staining was compared with that
of PAS and a-SMA1 staining. For this, horizontal serial sections
cut through the hilus of the right kidney of each animals were
stained for PAS, a-SMA1 or PDGF-BB. These sections were
viewed down a light microscope fitted with an X 20 fiat field
objective and the numbers of stained items were recorded. One
section per antibody and PAS stain for each rat was sampled
systematically by projecting a 16-square test lattice (total area 0.49
mm2) onto each field and the data were collected from 20
adjacent fields. The results are expressed as the mean number of
stained components per mm2.
Statistical analysis
Results are expressed as mean standard error of the mean.
The significance between groups was determined by analysis of
variance. A probability of less than 5% was taken as significant.
Results
General observations
Mean food consumption prior to treatment was about 18 g per
day/rat, while water consumption was 33 ml per day/rat. During
CsA treatment (25 mg/kg/day), food intake decreased to around
16 g/day over the first 2 weeks and then declined further to around
12 g/day thereafter. Water consumption remained unchanged
throughout. Over the 4 week injection period the gain in body
weight of these rats was only 45% of that of the control group
injected with olive oil alone (Table 1), but was similar to that of
the control group with restricted food intake (pair-fed control).
However, 8 weeks after cessation of CsA treatment there was no
significant difference in the mean body weight of the two groups
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Table 1. Comparison of CsA treated and olive oil-injected control and pair-fed control rats 1 to 4 weeks, and 8 weeks after 4 weeks of
CsA injections
1 Week
(N=12)
2 Weeks
(N=9)
3 Weeks
(N=6)
4 Weeks
(N=9)
12 Weeksa
(N=6)
Gain in body weight g %
Control
Pair-fed control
CsA
45 2(16)
19 3 (fi)b
75 6(27)
22 15 (87
94 10 (36)
43 15 (127
59 7 (21)t(
139 26(57)
72 9(287
77 16(19)
81 15 (25
Serum creatinine pinol/liter
Control 36±1 40±4 39±1 43±3 46±2
Pair-fed control 39 1'l
CsA 42÷l 56±2(1 64±3k' 6i±P' 53÷2
Creatinine clearance ml!
min/100 g body wt
Control 0.57 0.03 0.40 0.07 0.43 0.07 0,46 0.03 0.43 0.08
Pair-fed control 0.44 008
CsA 0.46 005d 0.28 007d 0.23 0.02C 0.10 0.01" 0.38 0.09"
Blood CsA levels pg/liter 2093 292 2830 285 2747 107 3500 325 Not detected
Data are means 5EM. N = 3.
a 8 weeks after withdrawal of treatment
bp < 0.01 vs. control
F C 0.05 vs. controld Not significant vs. control
Table 2. Comparison of CsA treated and control rats at sacrifice
Creatinine
Gain in body
weight g (%)
Serum
creatinine
p.'nol/liter
clearance
mI/min/100 g
body wt
Blood CsA
levels pg/liter
Control 139 26 (57) 43 3 0.46 0.03 —
5 mg/kg CsA
7.5 mg/kg CsA
123 mg/kg CsA
20 mg/kg CsA
122 11 (47)C
101 4 (33)C
84 8 (25)"
86 7(28)"
41 1
47 5C
59 1"
64
0.55 0.02c
0.42 0.09"
0.26 0.03"
0.19 o.o&
510 25
999 81
1917 63
2435 255
Data are means SEM. N = 3.
ap < 0.01
"p c 0.05
C Not significant
(Table 1). Body weight gain at sacrifice showed progressive
decline with increasing the dose of CsA (Table 2).
At the time of sacrifice there was no significant difference in
systolic blood pressure between CsA-treated (25 mg/kg/day) and
control or pair-fed rats (132 9 mm Hg vs. 130 5 mm Hg,
respectively). However, the systolic blood pressure of animals
subjected to partial ligation of the aorta reached 186 10 mm Hg
at the time of sacrifice compared with 109 8 mm Hg in control
animals (P < 0.05).
Renal function
Alter 3 weeks of treatment, serum creatinine levels were
significantly higher and creatinine clearance rates significantly
lower in the CsA treated group (25 mg/kg/day) compared with
control groups (Table 1). Eight weeks after cessation of CsA,
serum creatinine and creatinine clearance rates had returned to
normal levels (Table 1). In other CsA-treated rats, progressive
increase in serum creatinine and decline in creatinine clearance
rate were evident with increasing the dose of CsA (Table 2). In the
control group of rats subjected to partial ligation of the aorta,
renal function was also impaired with mean creatinine clearance
rate of 0.39 0.03 ml/min/100 g body wt.
Whole blood CsA reached 2093 292 jig/liter after 1 week and
3500 325 jig/liter after 4 weeks of treatment with CsA (25
mg/kg/day) (Table 1). CsA was not detectable in the blood 8
weeks after CsA withdrawal. In the dose response group, CsA
blood levels varied with the dose of CsA and showed progressive
rise with increasing the dose (Table 2).
Renal morphology
In rats injected with CsA (25 mg/kg/day), histological examina-
tion failed to detect any change in renal morphology for the first
2 weeks. After 3 weeks of CsA administration, the proximal
tubules displayed isometric vacuolation and large lysosome-like
inclusion bodies but the brush borders remained intact (Fig. 1). By
4 weeks, there was slight evidence of interstitial edema and
tubular atrophy. However, sections stained with Masson's
trichrome did not provide any evidence of interstitial fibrosis.
In these rats, the most consistent change occurred within the
blood vessels. After 1 week there was strong PAS staining of some
of the afferent arterioles (Fig. 2). The media of these appeared
thickened. The staining varied from amorphous to granular and
superficially resembled arteriolar hyalinosis. Staining also oc-
curred in the walls of some arterioles remote from the glomerulus
(Fig. 3). Withdrawal of CsA treatment caused reversal of all these
morphological changes and the strong staining of arteriolar walls
was no longer evident.
In the ischemic group, the ischemic left kidney displayed
proximal tubular vacuolation, distal tubular atrophy and intersti-
tial expansion. In these rats, no positive PAS staining was evident
within the cortical arterioles, In contrast, right kidneys displayed
hypertensive changes consistent of arteriolar hypertrophy, hyali-
nosis and increase in adventitial fibroblasts.
Immunohistochemistry
Incubation of control and CsA-treated sections with anti-a-
SMA1 provided an invaluable marker for both afferent and
intralobular arterioles. In all cases strong binding occurred to the
myocytes within the vessel walls (Fig. 4). Tissues from rats treated
a fl.; •: fl
— -S
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Fig. 1. Kidney tissue of CsA -treated after 4 weeks showing proximal tubular Fig. 4. Immunohistochemistiy; kidney tissue from control animal showing
vacuolation (Masson's trichrome stain X 400). staining of the afferent and intralobular arterioles with a-SM41. Staining is
localized to the muscle in the walls of the vessels (X 200).
Fig. 5. Immunohistochemistiy; kidney tissue from a CsA treated animal for
4 weeks demonstrating the immunostaining of the afferent arteriole with
Fig. 2. Kidney tissue of C5A treated rat showing strong staining of an afferent PDGF-BB antibody. Staining is mainly in the media of the vessel wall (X
arteriole (PAS stain X 400). 400).
Fig. 3. Kidney tissue of CsA treated rat showing strong PAS staining of an weeks showing PDGF-BB immunostaining in the intralobular arteriole (X
intralobular arteriole (X 400). 400).
FIg. 6. Jrn,.:tnohLsIorhemisgrq; kidney tissue from CsA treated ani,nuls for 4
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Table 3. Number of cortical arteriole profiles/mm2 tissue section which
stained with antibodies after various periods of CsA treatment
Week 1 Week 2 Week 3 Week 4
PASa
Control — — — —
CsA 0.26 0.09 0.38 0.15 0.29 0.03 0.32 0.05
a-SMA1
Control 3.66 0.43 4.02 0.09 3.92 0.75 3.90 0.53
CsA 3.00 0.56" 3.73 0.13" 4.07 0.31" 3.28 0.19"
PDGF-BW
Conrol — — — —
CsA 0.77 0.03 1.19 0.17 1.10 0.06 1.13 0.21
Data are means SCM. N = 3.
No specific staining is denoted by dash. N = 3.
No significant difference between weeks 1 and 4
b Values not significantly different from control
with CsA stained on incubation with the anti-PDGF-AB and
anti-PDGF-BB antibodies. Staining was evident within the walls
of some afferent (Fig. 5) and intralobular arterioles (Fig. 6). It was
consistently stronger when the anti-PDGF-BB antibody was ap-
plied but the pattern of staining with both antibodies was the
same. After 1 week of CsA treatment (25 mg/kg/day) about 26%
of arteriole profiles (as a percentage of those staining with
a-SMA1) were stained (Table 3). Thereafter, the number of
stained arteriole profiles did not increase significantly (Table 3)
but the intensity of staining did increase. Tissue taken at 8 weeks
after the withdrawal of CsA did not stain with either antibody.
PDGF-BB staining of the afferent and intralobular arterioles was
not detectable in rats given 5 mg/kg/day of CsA, but the immu-
nostain was apparent in those injected with higher doses. Tissue
from control and pair-fed control rats did not stain with any of the
PDGF antibodies. However, tissue from the left kidneys of
ischemia control group also showed weak to moderate staining
with the PDGF-BB antibody but no staining was evident in the
right (non-ischemic kidney).
No staining occurred when the anti-PDGF-AA antibody was
applied either to control, pair-fed, CsA treated or ischemic
kidneys. Incubations which omitted primary antibody or which
used primary antibodies that had been preabsorbed with purified
PDGF-BB antigen produced no staining of arterioles in any
tissue, On the other hand, preabsorption of the anti-PDGF-BB
antibody with purified renin did not affect the staining.
Discussion
In this study we have demonstrated strong immunostaining for
PDGF within the afferent and intralobular arterioles of rat
kidneys following the administration of nephrotoxic doses of CsA.
Although the dose of CsA (25 mg/kg/day) used in this study was
high compared to those used in humans, it has been suggested
that higher dosage is required in the rat to achieve nephrotoxicity
[31]. Furthermore, a similar PDGF staining pattern was observed
with a dose of 7,5 mg/kg/day which is comparable to that currently
used in clinical transplantation. Although a reduction in food
consumption accompanied by failure to gain weight was observed
with higher doses of CsA, the staining can not be attributed to
dietary changes as it did not occur in tissue from pair-fed controls.
The absence of staining when the drug was discontinued indicates
that, in this model, PDGF accumulates in the afferent arterioles as
a result of CsA administration. Staining was strongest when
PDGF-BB antibody was applied and no staining occurred when
the PDGF-AA antibody was used. Staining was abolished by
preabsorption of the antibody with the PDGF-BB antigen, sug-
gesting specificity of the antibody. This suggests that it is princi-
pally PDGF-BB which is being synthesized or accumulated, but
we cannot at this stage exclude the possibility that both PDGF-AB
and PDGF-BB isoforms are present. The appearance of the stain
within short segments of afferent arterioles close to the vascular
pole of the glomerulus leads us to suspect that the PDGF is
located in granular juxtaglomerular-like cells. Reassuringly, in our
studies, preabsorption of the PDGF-BB antibody with renin did
not affect the staining, suggesting that this antibody does not cross
react with renin.
It seems therefore that juxtaglomerular cells may also be
involved, directly or indirectly, in the synthesis or accumulation of
PDGF. Of interest, these cells have also been shown to express
immunostain for transforming growth factor-13 (TGF-13) in mice
deprived of water [321. However, our studies provide no evidence
that the appearance of PDGF is due to hypovolemia or water
deprivation as no staining was observed in the pair-fed, pair-
watered controls. These studies suggest that these cells within the
afferent arterioles, which regulate glomerular blood flow, are
capable of the synthesis or accumulation of more than one growth
factor in response to physiological or pathological stimuli.
Although hypertrophy of the juxtaglomerular cells, character-
ized by positive PAS staining of both afferent arterioles and those
remote from the glomerulus, has been reported to occur in
animals injected with nephrotoxic doses of CsA [33—35], these
changes are not specific to CsA nephrotoxicity as it has also been
described in rats subjected to chronic renal ischemia [28]. Of
interest in our study, the immunostaining for PDGF also occurred
in control rats subjected to chronic renal ischemia, suggesting a
link between CsA nephrotoxicity, ischemia and PDGF. The
presence of staining within the ischemic left kidney and its
absence in the right kidney of these rats seems to indicate that
ischemia, rather than hypertension or renal insufficiency, is the
stimulus for the appearance of PDGF in CsA treated rats.
The available evidence suggests that CsA-induced ischemia is
mediated through vasoconstriction of the afferent arterioles [11].
However, it is not clear whether CsA acts directly or whether its
effect is mediated by other vasoactive mediators. Hypertrophy of
the juxtaglomerular cells, in association with raised plasma renin
activity [6, 12, 14], has prompted some workers to suggest that
stimulation of the renin-angiotensin system mediates the hemo-
dynamic changes in these animal models. A recent study failed to
detect any increased renin mRNA in afferent arterioles of CsA-
treated rat kidneys [36] suggesting that post-translational mecha-
nisms are responsible for the observed increase in immunostain-
ing of these arterioles which occurred with anti-renin antibody.
However, inhibition of angiotensin II generation by captopril (an
angiotensin converting enzyme inhibitor) fails to abolish experi-
mental CsA-induced renal ischemia [6, 37, 38]. The stimulation of
thromboxane A2 [16, 39, 40] and the inhibition of prostaglandins
[41, 42] have also been suggested as mediators of CsA-induced
vasoconstriction; however, neither the administration of a throm-
boxane receptor antagonist [17, 42] nor prostaglandin analogues
[43] seems to fully protect against CsA-induced hemodynamic
changes.
The involvement of endothelin has recently been proposed [20,
21]. The level of this vasoconstricting growth factor is elevated in
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rat kidneys after chronic CsA administration [20]. This could
explain the increased vascular resistance and reduced blood flow
seen in isolated perfused kidneys exposed to CsA [21]. Evidence
for this is provided by the fact that the application of an
anti-endothelin antibody effectively prevents CsA-induced renal
hypoperfusion both in isolated kidneys [21] and in vivo [22].
Many of the putative mediators of CsA-induced renal vasocon-
striction have also been linked to the response of the kidney to
ischemia. This also appears to be the case with PDGF, as we have
detected it in both CsA-treated and ischemic kidneys. However, it
remains unclear whether these vasoactive mediators play a pri-
maiy or secondary role in CsA-induced renal ischemia. PDGF is
a potent renal vasoconstrictor through a direct effect on glomer-
ular microcirculation [44] and possibly through its interaction with
some of the better known renal vasoactive autacoids such as
angiotensin II [45] and endothelin [46].
PDGF is also a potent mitogen which has been shown to induce
stimulation of fibroblast proliferation and collagen synthesis [25].
It may be, therefore, that PDGF is also associated with the fibrosis
and scarring which occurs during chronic CsA administration.
Also, arteriolopathy which is characteristic of human CsA neph-
rotoxicity may be linked to increased synthesis or accumulation of
PDGF, as these lesions are similar to atherosclerotic ones in
which PDGF-BB and its receptors have been shown to be
involved [26, 27].
To the best of our knowledge this is the first report of the
presence of PDGF in the afferent and intralobular arterioles of rat
kidneys injected with CsA or subjected to renal ischemia. It
remains to be determined whether the detected increase in
immunostainable PDGF within the kidneys of CsA-treated rats is
due to increased synthesis or binding. Further studies involving
the inhibition of PDGF synthesis, binding or action are needed to
determine the contribution of this mitogenic peptide and the links
between PDGF, other growth factors and renal autacoids in
CsA-induced renal dysfunction.
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